Hemogenyx Pharmaceuticals Plc (LON: HEMO)
London
· Delayed Price · Currency is GBP · Price in GBX1.200
-0.325 (-21.31%)
Nov 22, 2024, 6:56 PM BST
Hemogenyx Pharmaceuticals Balance Sheet
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Cash & Equivalents | 1.64 | 1.25 | 2.53 | 6.84 | 1.81 | 0.5 | Upgrade
|
| Cash & Short-Term Investments | 1.64 | 1.25 | 2.53 | 6.84 | 1.81 | 0.5 | Upgrade
|
| Cash Growth | -46.75% | -50.74% | -62.98% | 277.47% | 263.42% | -71.71% | Upgrade
|
| Other Receivables | 0.83 | 0.01 | 0.01 | 0.01 | 0.06 | 0.03 | Upgrade
|
| Receivables | 0.83 | 0.01 | 0.01 | 0.01 | 0.06 | 0.03 | Upgrade
|
| Prepaid Expenses | - | 0.92 | 0.05 | 0.29 | 0.05 | 0.02 | Upgrade
|
| Total Current Assets | 2.47 | 2.17 | 2.59 | 7.14 | 1.92 | 0.55 | Upgrade
|
| Property, Plant & Equipment | 3.01 | 3.31 | 3.92 | 0.8 | 0.27 | 0.23 | Upgrade
|
| Other Intangible Assets | 0.47 | 0.47 | 0.44 | 0.44 | 0.25 | 0.26 | Upgrade
|
| Long-Term Deferred Charges | - | - | - | - | 0.22 | - | Upgrade
|
| Other Long-Term Assets | 0.17 | 0.15 | 0.14 | 0.14 | - | - | Upgrade
|
| Total Assets | 6.12 | 6.11 | 7.09 | 8.52 | 2.66 | 1.05 | Upgrade
|
| Accounts Payable | 0.31 | 0.3 | 0.37 | 0.3 | 0.11 | 0.06 | Upgrade
|
| Accrued Expenses | - | 0.08 | 0.05 | 0.05 | 0.05 | 0.08 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | - | - | 1.58 | - | Upgrade
|
| Current Portion of Leases | 0.26 | 0.27 | 0.32 | 0.01 | 0.04 | 0.04 | Upgrade
|
| Total Current Liabilities | 0.56 | 0.65 | 0.75 | 0.35 | 1.78 | 0.18 | Upgrade
|
| Long-Term Debt | - | - | - | - | - | 1.14 | Upgrade
|
| Long-Term Leases | 2.53 | 2.67 | 3.1 | - | 0.01 | 0.07 | Upgrade
|
| Total Liabilities | 3.09 | 3.32 | 3.85 | 0.35 | 1.79 | 1.4 | Upgrade
|
| Common Stock | 13.42 | 11.76 | 9.8 | 9.8 | 4.34 | 3.61 | Upgrade
|
| Additional Paid-In Capital | 21.44 | 19.94 | 16.81 | 16.81 | 9.99 | 7.7 | Upgrade
|
| Retained Earnings | -26.62 | -23.8 | -17.11 | -13.13 | -8.04 | -5.95 | Upgrade
|
| Comprehensive Income & Other | -5.17 | -5.07 | -6.22 | -5.28 | -5.4 | -5.71 | Upgrade
|
| Total Common Equity | 3.06 | 2.82 | 3.28 | 8.19 | 0.89 | -0.35 | Upgrade
|
| Minority Interest | -0.04 | -0.04 | -0.03 | -0.02 | -0.02 | -0 | Upgrade
|
| Shareholders' Equity | 3.02 | 2.78 | 3.24 | 8.17 | 0.88 | -0.35 | Upgrade
|
| Total Liabilities & Equity | 6.12 | 6.11 | 7.09 | 8.52 | 2.66 | 1.05 | Upgrade
|
| Total Debt | 2.78 | 2.95 | 3.42 | 0.01 | 1.63 | 1.26 | Upgrade
|
| Net Cash (Debt) | -1.14 | -1.7 | -0.89 | 6.83 | 0.18 | -0.76 | Upgrade
|
| Net Cash Growth | - | - | - | 3609.03% | - | - | Upgrade
|
| Net Cash Per Share | -0.00 | -0.00 | -0.00 | 0.01 | 0.00 | -0.00 | Upgrade
|
| Filing Date Shares Outstanding | 1,342 | 1,342 | 1,142 | 979.75 | 433.64 | 397.25 | Upgrade
|
| Total Common Shares Outstanding | 1,342 | 1,176 | 979.75 | 979.75 | 433.64 | 361.24 | Upgrade
|
| Working Capital | 1.91 | 1.52 | 1.85 | 6.79 | 0.14 | 0.37 | Upgrade
|
| Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | -0.00 | Upgrade
|
| Tangible Book Value | 2.59 | 2.35 | 2.83 | 7.75 | 0.64 | -0.61 | Upgrade
|
| Tangible Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | -0.00 | Upgrade
|
| Machinery | - | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | Upgrade
|
| Leasehold Improvements | - | 0.69 | 0.72 | 0.64 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.